Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.

Brams M, Turnbow J, Pestreich L, Giblin J, Childress A, McCague K, Muniz R.

J Clin Psychopharmacol. 2012 Oct;32(5):637-44. doi: 10.1097/JCP.0b013e3182677825. Erratum in: J Clin Psychopharmacol. 2012 Dec;32(6):766.

PMID:
22926597
3.

Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.

Silva RR, Brams M, McCague K, Pestreich L, Muniz R.

Clin Neuropharmacol. 2013 Jul-Aug;36(4):117-21. doi: 10.1097/WNF.0b013e31829aa92c.

PMID:
23860345
4.

Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.

Silva RR, Muniz R, Pestreich L, Brams M, Mao AR, Childress A, Wang J.

J Am Acad Child Adolesc Psychiatry. 2008 Feb;47(2):199-208. doi: 10.1097/chi.0b013e31815cd9a4.

PMID:
18176337
5.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
6.

Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.

Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R.

J Child Adolesc Psychopharmacol. 2008 Jun;18(3):248-56. doi: 10.1089/cap.2007.0015.

PMID:
18582179
7.

Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.

Silva RR, Muniz R, Pestreich L, Childress A, Brams M, Lopez FA, Wang J.

J Child Adolesc Psychopharmacol. 2006 Jun;16(3):239-51.

PMID:
16768632
8.

A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.

Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R.

CNS Drugs. 2008;22(8):693-704.

PMID:
18601306
9.

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.

Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H.

J Am Acad Child Adolesc Psychiatry. 2006 Jul;45(7):817-23.

PMID:
16832318
10.

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Greenhill LL, Findling RL, Swanson JM; ADHD Study Group.

Pediatrics. 2002 Mar;109(3):E39.

PMID:
11875167
11.

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.

Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.

J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1406-14.

PMID:
15502600
12.

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L; Adult ADHD Research Group.

Biol Psychiatry. 2007 Jun 15;61(12):1380-7. Epub 2006 Nov 29.

PMID:
17137560
13.

Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.

Silva R, Muniz R, Pestreich LK, Brams M, Childress A, Lopez FA.

J Child Adolesc Psychopharmacol. 2005 Aug;15(4):637-54.

PMID:
16190795
14.

A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.

Wigal SB, Greenhill LL, Nordbrock E, Connor DF, Kollins SH, Adjei A, Childress A, Stehli A, Kupper RJ.

J Child Adolesc Psychopharmacol. 2014 Dec;24(10):562-9. doi: 10.1089/cap.2014.0100.

16.

Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.

Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B.

Curr Med Res Opin. 2011;27 Suppl 2:35-44. doi: 10.1185/03007995.2011.601733. Epub 2011 Jul 25.

PMID:
21787126
19.

Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.

Adler LA, Spencer T, McGough JJ, Jiang H, Muniz R.

J Atten Disord. 2009 Mar;12(5):449-59. doi: 10.1177/1087054708320397.

PMID:
19218542
20.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303

Supplemental Content

Support Center